Compare Enveric Biosciences Inc (ENVB) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Banco Santander SA — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Banco Santander SA trades at $14.78 (market cap $211.88B). The key difference: Banco Santander SA is far larger — about 34174.2× Enveric Biosciences Inc's market cap, and Banco Santander SA pays a 1.89% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | SAN | |
|---|---|---|
Market Cap | $6.20M | $211.88B |
Sector | Health | Financials |
52-Week High | $17.40 | $14.71 |
52-Week Low | $1.27 | $9.37 |
Enterprise Value | $1.30M | — |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Banco Santander (SAN) trades at $14.70, up 0.34% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 14.39, net income margin of 26.25% for 2026, and record profits in H1 2026. Recent news highlights Federal Reserve approval for its $12 billion Webster Bank acquisition, expected to close August 20, 2026, and its rise as Spain's most valuable company.
Outlook is positive given analyst consensus (64% buy ratings), solid profitability, and strategic acquisitions, but risks include regulatory scrutiny in Spain, volatile cash flows, and earnings misses in two of the last three quarters. The stock offers value with growth potential amid integration execution and macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
